11 research outputs found
Finishing the euchromatic sequence of the human genome
The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead
Incompatibility with Formin Cdc12p Prevents Human Profilin from Substituting for Fission Yeast Profilin: INSIGHTS FROM CRYSTAL STRUCTURES OF FISSION YEAST PROFILIN*S⃞
Expression of human profilin-I does not complement the
temperature-sensitive cdc3-124 mutation of the single profilin gene
in fission yeast Schizosaccharomyces pombe, resulting in death from
cytokinesis defects. Human profilin-I and S. pombe profilin have
similar affinities for actin monomers, the FH1 domain of fission yeast formin
Cdc12p and poly-l-proline (Lu, J., and Pollard, T. D. (2001)
Mol. Biol. Cell 12, 1161–1175), but human profilin-I does not
stimulate actin filament elongation by formin Cdc12p like S. pombe
profilin. Two crystal structures of S. pombe profilin and homology
models of S. pombe profilin bound to actin show how the two profilins
bind to identical surfaces on animal and yeast actins even though 75% of the
residues on the profilin side of the interaction differ in the two profilins.
Overexpression of human profilin-I in fission yeast expressing native profilin
also causes cytokinesis defects incompatible with viability. Human profilin-I
with the R88E mutation has no detectable affinity for actin and does not have
this dominant overexpression phenotype. The Y6D mutation reduces the affinity
of human profilin-I for poly-l-proline by 1000-fold, but
overexpression of Y6D profilin in fission yeast is lethal. The most likely
hypotheses to explain the incompatibility of human profilin-I with Cdc12p are
differences in interactions with the proline-rich sequences in the FH1 domain
of Cdc12p and wider “wings” that interact with actin
OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin
Organic cation transporter 1, OCT1 (SLC22A1), is the major hepatic uptake transporter for metformin, the most prescribed antidiabetic drug. However, its endogenous role is poorly understood. Here we show that similar to metformin treatment, loss of Oct1 caused an increase in the ratio of AMP to ATP, activated the energy sensor AMP-activated kinase (AMPK), and substantially reduced triglyceride (TG) levels in livers from healthy and leptin-deficient mice. Conversely, livers of human OCT1 transgenic mice fed high-fat diets were enlarged with high TG levels. Metabolomic and isotopic uptake methods identified thiamine as a principal endogenous substrate of OCT1. Thiamine deficiency enhanced the phosphorylation of AMPK and its downstream target, acetyl-CoA carboxylase. Metformin and the biguanide analog, phenformin, competitively inhibited OCT1-mediated thiamine uptake. Acute administration of metformin to wild-type mice reduced intestinal accumulation of thiamine. These findings suggest that OCT1 plays a role in hepatic steatosis through modulation of energy status. The studies implicate OCT1 as well as metformin in thiamine disposition, suggesting an intriguing and parallel mechanism for metformin and its major hepatic transporter in metabolic function
OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin
Organic cation transporter 1, OCT1 (SLC22A1), is the major hepatic uptake transporter for metformin, the most prescribed antidiabetic drug. However, its endogenous role is poorly understood. Here we show that similar to metformin treatment, loss of Oct1 caused an increase in the ratio of AMP to ATP, activated the energy sensor AMP-activated kinase (AMPK), and substantially reduced triglyceride (TG) levels in livers from healthy and leptin-deficient mice. Conversely, livers of human OCT1 transgenic mice fed high-fat diets were enlarged with high TG levels. Metabolomic and isotopic uptake methods identified thiamine as a principal endogenous substrate of OCT1. Thiamine deficiency enhanced the phosphorylation of AMPK and its downstream target, acetyl-CoA carboxylase. Metformin and the biguanide analog, phenformin, competitively inhibited OCT1-mediated thiamine uptake. Acute administration of metformin to wild-type mice reduced intestinal accumulation of thiamine. These findings suggest that OCT1 plays a role in hepatic steatosis through modulation of energy status. The studies implicate OCT1 as well as metformin in thiamine disposition, suggesting an intriguing and parallel mechanism for metformin and its major hepatic transporter in metabolic function
Young People and School GCSE Attainment: Exploring the 'Middle'
The term 'missing middle' has been used to describe the position of ordinary young people in youth research. There have been recent appeals for youth researchers to concentrate upon the lives of ordinary young people and to better document their educational experiences through the secondary analysis of large-scale social surveys. This paper presents a series of exploratory analyses that attempt to identify the school-level educational attainment and social characteristics of ordinary young people using contemporary survey data
Recommended from our members
The genomic and epigenomic landscape of double-negative metastatic prostate cancer.
Systemic targeted therapy in prostate cancer is primarily focused on ablating androgen signaling. Androgen deprivation therapy and second-generation androgen receptor (AR)-targeted therapy selectively favor the development of treatment-resistant subtypes of metastatic castration-resistant prostate cancer (mCRPC), defined by AR and neuroendocrine (NE) markers. Molecular drivers of double-negative (AR-/NE-) mCRPC are poorly defined. In this study, we comprehensively characterized treatment-emergent mCRPC by integrating matched RNA sequencing, whole-genome sequencing, and whole-genome bisulfite sequencing from 210 tumors. AR-/NE- tumors were clinically and molecularly distinct from other mCRPC subtypes, with the shortest survival, amplification of the chromatin remodeler CHD7, and PTEN loss. Methylation changes in CHD7 candidate enhancers were linked to elevated CHD7 expression in AR-/NE+ tumors. Genome-wide methylation analysis nominated KLF5 as a driver of the AR-/NE- phenotype, and KLF5 activity was linked to RB1 loss. These observations reveal the aggressiveness of AR-/NE- mCRPC and could facilitate the identification of therapeutic targets in this highly aggressive disease